Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment.

Neuropsychiatr Dis Treat · 2022 · PMC9792103 · PMID 36578903

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The initial study at week 26, reported more eculizumab-treated patients achieving “minimal symptom expression” than placebo (MG-ADL: 21.4% vs 1.7%; and MG-QOL15: 16.1% vs 1.7%) both highly significant differences.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.